Author

Ahmed Madisch 1

1 Klinikum Siloah, Hannover, Germany

A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Stephan Miehlke, Alfredo J. Lucendo, Christoph Schlag, Ulrike von Arnim, Javier Molina Infante, Christoph Schmöcker, Albert Jan Bredenoord, Constanza Ciriza De Los Ríos, Stefan Brückner, Ahmed Madisch, Stefan Schubert, Jamal Hayat, Stephen E. Attwood, Jan Tack, Ralph Mueller, Roland Greinwald, Alex Straumann, Alain M. Scho

A novel budesonide orodispersible tablet formulation is highly effective to maintain endoscopic inflammatory remission and even complete endoscopic remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Luc Biedermann, Alfredo J. Lucendo, Stephan Miehlke, Christoph Schlag, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen E. Attwood, Alex Straumann

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, EUROPEAN MULTICENTRE TRIAL OF TWO NEW BUDESONIDE FORMULATIONS FOR TREATMENT OF ACTIVE EOSINOPHILIC ESOPHAGITIS

Petr Hruz, Stephan Miehlke, Ulrike von Arnim, Ahmed Madisch, Michael Vieth, Christiane Fibbe, Henning Wittenburg, Hans-Dieter Allescher, Max Reinshagen, Stefan Schubert, Jan Tack, Michaela Müller, Alexander J. Eckardt, Patrick Krummenerl, Joris Arts, Karin Dilger, Roland Greinwald, Alex Straumann

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Luc Biedermann, Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Michael Vieth, Christoph Schlag, Cecilio Santander, Constanza Ciriza de Los Rios, Christoph Schmöcker, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Stefan Schubert, Ralph Mueller, Roland Greinwald, Alain M. Schoepfer, Stephe

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Ralph Mueller, Christoph Schlag, Christoph Schmöcker, Roland Greinwald, Luc Biedermann, Michael Vieth, Alfredo J. Lucendo, Cecilio Santander, Alex Straumann, Petr Hruz, Ahmed Madisch, Stephan Miehlke, Stephen E. Attwood, Arjan Bredenoord, Stefan Schubert, Constanza Ciriza De Los Ríos, Alain M. Schoepfer, Jamal Hayat, Ulri

BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL

Christoph Schlag, Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Luc Biedermann, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Christoph Schmöcker, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Albert Jan Bredenoord, Ralph Mueller, Roland Greinwald, Alain M. Schoepfer, Stephen E. Attwood, Stefan

Budesonide orodispersible tablets are superior to maintain and even further improve quality of life in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Christoph Schlag, Luc Biedermann, Alfredo J. Lucendo, Stephan Miehlke, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen E. Attwood, Alex Straumann

Budesonide orodispersible tablets are superior to maintain combined clinical and histological remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Michael Vieth, Christoph Schlag, Luc Biedermann, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Stefan Schubert, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen

DISTRIBUTION OF DIAGNOSTIC CRITERIA FOR COLLAGENOUS COLITIS – POOLED ANALYSIS OF 2 EUROPEAN CLINICAL TRIALS

Stephan Miehlke, Daniela Aust, Ole Kristian Bonderup, Johan Bohr, Ahmed Madisch, Michael Vieth, Henrik Hjortswang, Fernando Fernández-Bañares, Curt Tysk, Magnus Strom, Ralph Mueller, Roland Greinwald, Andreas Münch, Ralf Mohrbacher

EFFICACY AND SAFETY OF BUDESONIDE ORODISPERSIBLE TABLETS IN ACTIVE EOSINOPHILIC OESOPHAGITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PIVOTAL, EUROPEAN MULTICENRE TRIAL (EOS-1)

Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Michael Vieth, Christoph Schlag, Ulrike von Arnim, Javier Molina Infante, Dirk Hartmann, Arjan Bredenoord, Constanza Ciriza De Los Ríos, Stefan Schubert, Stefan Brueckner, Ahmed Madisch, Jamal Hayat, Jan Tack, Alain Schoepfer, Roland Greinwald, Ralph Mueller, Stephen E.

Item 1 - 10 / 20
1
2